IP Library Granted Patent US 9,766,250
Granted Patent B2
US 9,766,250 · App. 15/273,815 · Granted Sep 19, 2017

Method for detecting protein-protein interaction

Inventors: Taku Watanabe (Ina, JP); Tatsuya Seki (Ina, JP); Aki Fujioka (Ina, JP)
Assignee: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
G01N33/6845C12N15/85G01N33/542G01N33/582G01N2500/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,766,250
App. No.
15/273,815
Granted
Sep 19, 2017
Kind
B2
Abstract

A method for detecting an interaction between a first protein and a second protein comprises the steps of: expressing in a cell a first fusion protein comprising the first protein and an association-inducing protein, and a second fusion protein comprising the second protein and a fluorescent protein having a multimerization ability; detecting a fluorescent focus formed by an association between the first fusion protein and the second fusion protein in the cell; and determining an interaction between the first protein and the second protein according to the detection of the fluorescent focus.

Claims (8)

1. A method for screening for a substance modulating an interaction between a first protein and a second protein, the method comprising the steps of:

expressing in a cell a first fusion protein comprising the first protein and an association-inducing protein, and a second fusion protein comprising the second protein and a fluorescent protein having a multimerization ability and emitting fluorescence, in presence of a test compound;

detecting a fluorescent focus formed by an association between the first fusion protein and the second fusion protein in the cell; and

selecting the test compound as a substance inducing the interaction if a fluorescence intensity of the fluorescent focus is higher than a fluorescence intensity of a fluorescent focus formed in absence of the test compound, or selecting the test compound as a substance suppressing the interaction if the fluorescence intensity of the fluorescent focus is lower than the fluorescence intensity of the fluorescent focus formed in the absence of the test compound, wherein

the association-inducing protein is at least one protein selected from the group consisting of a PB1 domain of p62, a PB1 domain of TFG, a PB1 domain of PKCiota, a SAM domain of TEL, a SAM domain of DGK delta, and a SAM domain of Tankyrase-1;

the fluorescent protein having a multimerization ability is at least one fluorescent protein selected from the group consisting of a florescent protein capable of forming a homomultimer, monomeric Kusabira-Orange 2, monomeric Keima-Red, monomeric Midoriishi-Cyan1, monomeric Kusabira-Orange 1, and monomeric Kikume Green-Red1;

the fluorescent focus has a fluorescence intensity in a region of 0.2 to 5 μm, the fluorescence intensity being higher than a fluorescence intensity of the fluorescent protein having a multimerization ability, which is present in a dispersed state in the cell, and

the association inducing protein is able to form a fluorescent focus when fused to the fluorescent protein having a multimerization ability.

Assignments (1)
CHANGE OF ADDRESS Recorded Oct 28, 2022
From: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
To: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
Reel/Frame 061794/0822 →
Priority Claims (1)
JP 2011-266103 · Dec 5, 2011 · national
Continuity (2)
Division 14363201
Related Publication 20170010277A1 · Jan 12, 2017